Navigation Links
Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
Date:2/9/2010

DEERFIELD, Ill., Feb. 9 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

This clinical trial, titled "A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects," is currently enrolling subjects and is expected to be completed within the 2010 calendar year. The randomized, open-label, single-center, multiple-dose, 2-period, crossover study is designed to assess the effects of multiple oral doses of four once-daily PPIs on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy subjects. Clopidogrel is a drug that is indicated for the reduction of atherothrombotic events, such as recent myocardial infarction, recent stroke, established peripheral arterial disease, or acute coronary syndrome.

According to a recent FDA announcement, studies have shown that omeprazole inhibits a liver enzyme (CYP2C19) important for the activation of clopidogrel. With CYP2C19 inhibition, clopidogrel will have reduced anticlotting effects, thereby reducing its effectiveness. The FDA has recommended that co-administration of omeprazole and other potent CYP2C19 inhibitors, including esomeprazole, be avoided in patients taking clopidogrel. It is unknown how other PPIs may interfere with Plavix.

"The extent to which each PPI is metabolized by the liver enzyme CYP2C
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... ROBLES, Calif. , Aug. 29, 2014  Pacific ... of its new website design . The main ... overhaul that showcases the company,s new services and content ... By implementing a new streamlined design, viewers can now ... metrics for health care practices and create a more ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2
... ORANGE, Calif., March 16, 2011 To ... beautiful smiles for their patients, leading orthodontic appliance innovator ... Ormco Loyalty Rewards program. Designed to ... selection of orthodontic appliances to treat their patients, the ...
... U L URUI nc. (NYSE Amex: ... an abbreviated 510(k) application with the U.S. Food and Drug ... and mitigation of pain. The principal data supporting ... to Acquacel® Ag in skin graft donor sites. This amended ...
Cached Medicine Technology:Ormco Launches New Loyalty Rewards Program 2Ormco Launches New Loyalty Rewards Program 3ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... 2014 LiveOps, Inc., the global leader ... announced that LiveOps has been selected as a call ... of Strength Telethon for the third year in a ... awareness to support MDA’s mission to help children and ... fatal muscle disease. This year’s program includes performances by ...
(Date:8/29/2014)... Reinberg HealthDay Reporter ... majority of American babies are getting the vaccines they ... officials said Thursday. More than 90 percent of ... and rubella (MMR); polio; hepatitis B and chickenpox (varicella), ... Prevention. "Nationally, vaccination among children 19 to 35 ...
(Date:8/29/2014)... 29, 2014 Floors of hospitals and ... wearing socks. Also, many patients are relegated to lying ... surgery recovery, Alzheimer’s, etc. Two inventors from Perrysburg, Ohio, ... patient safety. , This special pair of socks helps ... keeps patients who are relegated to beds or chairs ...
(Date:8/29/2014)... cigarettes in plain packages doesn,t increase the use of ... small stores, according to new research from Australia. ... it tried to prevent Australia from becoming the first ... tobacco products in 2012. Similar legislation is being considered ... surveyed nearly 2,000 adult smokers in Australia before and ...
Breaking Medicine News(10 mins):Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Study Counters Critics of Plainer Cigarette Packaging 2
... New findings from the St. Jude Children,s Research Hospital ... helped identify the mechanism that makes the childhood eye ... tumor develops so rapidly while other cancers can take ... also led investigators to a new treatment target and ...
... launched a freely available website for published research results ... University Pediatric Cancer Genome Project (PCGP). The PCGP is ... entire genomes of both normal and cancer cells from ... identify genetic mistakes that lead to childhood cancers. ...
... MADISON Placing a stent in a key artery in the ... standard surgical treatment of carotid artery disease, according to a ... Vascular Surgery . A team of researchers led ... at University of Wisconsin School of Medicine and Public Health, ...
... 11 (HealthDay News) -- Keeping an eye on Internet search ... an early warning system about potential surges in seasonal flu ... more effective than waiting for outdated government flu case reports, ... reviewed Google Flu Trends data for Baltimore and matched that ...
... laboratory tests of an imaging agent that shows promise for ... brain signs that now can,t confirm a diagnosis until ... ACS Medicinal Chemistry Letters . Masahiro Ono and ... now exists for AD, which is claiming an increasingly heavy ...
... to condescendingly, excluded from a meeting, or ignored by a ... differently depending on whether your co-worker is a man or ... incivility towards colleagues feel negative emotions especially when the ... work, by Kathi Miner from Texas A&M University and Angela ...
Cached Medicine News:Health News:Gene identified as a new target for treatment of aggressive childhood eye tumor 2Health News:Gene identified as a new target for treatment of aggressive childhood eye tumor 3Health News:St. Jude Children's Research Hospital launches data website for genome project 2Health News:Stenting for stroke prevention becoming safer in high-risk patients 2Health News:Internet Flu Searches May Warn of Outbreaks 2Health News:'I feel your pain ...' 2
... Plus Instrument for applications ... ,The VERSASTEP™ Plus ... working length is a ... utilizing radial dilation. It ...
... system device is comprised of the following ... access port are also packaged in the ... cone with 12 mm Step™ cannula assembly ... 12 mm locking cone with 10/12 mm ...
... The Step™ and Mini Step™ device components are ... Step™ Single Use System is supplied sterile in ... packaged in various configurations and combinations. They are ... Access needle and the Step™ radially Expandable Sleeve. ...
... The Premium One-Step™ single-use system device is ... ,The device components for creating each access ... configurations: , Step™ insufflation and access ... packaged separately. , Step™ radially expandable sleeve, ...
Medicine Products: